Dr. Scott Kopetz, MD
Claim this profileMD Anderson Cancer Center
Area of expertise
Colorectal Cancer
Scott Kopetz, MD has run 7 trials for Colorectal Cancer. Some of their research focus areas include:
Pancreatic Cancer
Scott Kopetz, MD has run 5 trials for Pancreatic Cancer. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
University Of Texas MD Anderson Cancer Center
Clinical Trials Scott Kopetz, MD is currently running
CAR T-Cell Preparation
for Cancer
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Recruiting
1 award
N/A
3 criteria
M9140
for Colorectal Cancer
This trial is testing a new drug called M9140 to see if it is safe and effective for patients with advanced solid tumors. Researchers will study how the drug behaves in the body, how well patients can tolerate it, and if it shows any signs of fighting the cancer.
Recruiting
1 award
Phase 1
More about Scott Kopetz, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Scott Kopetz, MD has experience with
- CAR T-Cell Therapy
- Autologous TCR-T Cells
- Autologous T Cells To Express T-Cell Receptors (TCRs)
- Aldesleukin (IL-2)
- Autologous T Cells Using The Sleeping Beauty System To Express TCRs
- Aspirin
Breakdown of trials Scott Kopetz, MD has run
Colorectal Cancer
Pancreatic Cancer
Lung Cancer
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Kopetz, MD specialize in?
Scott Kopetz, MD focuses on Colorectal Cancer and Pancreatic Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Scott Kopetz, MD currently recruiting for clinical trials?
Yes, Scott Kopetz, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Scott Kopetz, MD has studied deeply?
Yes, Scott Kopetz, MD has studied treatments such as CAR T-Cell Therapy, Autologous TCR-T Cells, Autologous T Cells to Express T-Cell Receptors (TCRs).
What is the best way to schedule an appointment with Scott Kopetz, MD?
Apply for one of the trials that Scott Kopetz, MD is conducting.
What is the office address of Scott Kopetz, MD?
The office of Scott Kopetz, MD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.